Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: GlobeNewswire
Positive topline data from Phase 2 HORIZON trial of MZE829 demonstrating first clinical proof-of-concept in patients with broad AMKD to support advancement into pivotal program; Maze to host conference call today at 8:00 am EDT Two Phase 2 proof-of-concept clinical trials evaluating MZE782 in PKU and CKD expected to initiate in 2026 Industry leader Neil Kumar, Ph.D., Founder and CEO of BridgeBio, appointed to Maze Board of Directors Strong balance sheet with $360.0 million in cash, cash equivalents and marketable securities; expected cash runway into 2028 SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the fourth quarter and year ended December 31, 2025, highlighting recent progress and business updates. “We are proud of the progress that Maze achieve
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
- Maze Therapeutics (MAZE) had its "buy" rating reaffirmed by BTIG Research. They now have a $46.00 price target on the stock.MarketBeat
- Maze Therapeutics (MAZE) had its price target raised by HC Wainwright from $60.00 to $110.00. They now have a "buy" rating on the stock.MarketBeat
- Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney DiseaseGlobeNewswire
- Maze Therapeutics President Sells All Insider Shares as Q4 Earning Report Nears [Yahoo! Finance]Yahoo! Finance
MAZE
Earnings
- 3/25/26 - Beat
MAZE
Sec Filings
- 3/25/26 - Form 10-K
- 3/25/26 - Form 8-K
- 3/20/26 - Form 4
- MAZE's page on the SEC website